ArticleAmerican journal of cancer research2026
Timing of multiple primary malignancies does not affect overall survival in lymphoma patients: a comparative study of 167 synchronous vs. metachronous cases.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, growing attention has been paid to the clinical management and prognosis of lymphoma patients with multiple primary malignancies (MPMs). This study aimed to determine whether the timing of MPM diagnosis affects the clinical characteristics and prognosis of these patients. A total of 167 patients with lymphoma complicated by MPMs were retrospectively analyzed. Patients were divided into a synchronous cancer group (SC, interval ≤6 months between diagnoses) and a metachronous cancer group (MC, interval >6 months) based on the interval between the diagnoses of lymphoma and the second malignancy. Clinical characteristics were recorded and compared between the two groups. Overall survival (OS) was estimated using the Kaplan-Meier method, and independent prognostic factors were identified through a multivariate Cox proportional hazards regression analysis. No significant differences were observed in baseline clinical characteristics between the SC and MC groups. The 1-, 3-, and 5-year OS rates for the entire cohort were 94.01%, 74.25%, and 72.46%, respectively. Multivariate analysis revealed that aggressive lymphoma (hazard ratio [HR]=2.618; 95% confidence interval [CI], 1.169-5.863; P=0.026) and Ann Arbor stages III-IV (HR=5.793; 95% CI, 2.658-12.625; P<0.005) were independent predictors of poor prognosis. The temporal sequence of MPMs was not identified as a significant factor influencing OS. Overall, prognosis in patients with lymphoma with MPMs is determined primarily based on the biological behavior and treatment response of lymphoma, whereas the diagnostic interval and sequence of MPM occurrence do not appear to significantly affect long-term survival. These results highlight the importance of focusing on lymphoma-specific features and treatment response in prognostic evaluation of patients with lymphoma with MPMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.